Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR017 in aggressive B-cell NHL
NCT03484702Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2018
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 11
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), primary central nervous system lymphoma (PCNSL), sponsored by Celgene Corporation. Started Jun 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03484702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484702.